VCA
IBB icon

Verdence Capital Advisors’s iShares Biotechnology ETF IBB Stock Holding History

Verdence Capital Advisors’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,694
Closed -$286K – 701
2025
Q4 		$286K Buy
+1,694
New +$275K 0.02% 546

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Verdence Capital Advisors's IBB Position: Q1 2026 in Review

Verdence Capital Advisors sold out of iShares Biotechnology ETF (IBB) in Q1 2026, closing a stake of 1,694 shares — an estimated $286K sold.

Verdence Capital Advisors first reported a position in IBB in Q4 2025 and held it in 1 quarter. The position peaked at $286K in Q4 2025. 920 funds tracked by Wall St. Rank hold IBB as of Q1 2026.

  • Verdence Capital Advisors reported no remaining iShares Biotechnology ETF position as of Q1 2026 after selling out during the quarter.
  • Verdence Capital Advisors sold 1,694 iShares Biotechnology ETF shares in Q1 2026, an estimated $286K.
  • Verdence Capital Advisors first reported a position in iShares Biotechnology ETF in Q4 2025 and held it in 1 quarter.
  • Verdence Capital Advisors's iShares Biotechnology ETF position peaked at $286K in Q4 2025.
  • 920 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2026.

Based on Verdence Capital Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.